Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Neurocognitive and Research Laboratory, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer. 2018 Apr 1;124(7):1326-1334. doi: 10.1002/cncr.31153. Epub 2018 Jan 16.
Androgen-deprivation therapy (ADT) remains the cornerstone of management for patients with metastatic prostate cancer. Although the toxicities of ADT are well established, there is increasing controversy surrounding the association between cognitive dysfunction and the receipt of ADT, with some evidence suggesting an increased risk of dementia. The authors conducted a literature search to identify pertinent clinical studies in this field. This general review outlines the key findings and discusses the relative strengths and weaknesses when drawing conclusions about the risk of cognitive dysfunction or dementia with ADT use. Cancer 2018;124:1326-34. © 2018 American Cancer Society.
去势治疗（ADT）仍然是转移性前列腺癌患者管理的基石。尽管 ADT 的毒性作用已得到充分证实，但关于认知功能障碍与 ADT 治疗之间的关联仍存在争议，一些证据表明 ADT 治疗会增加痴呆的风险。作者进行了文献检索，以确定该领域的相关临床研究。本综述概述了主要发现，并讨论了在得出关于 ADT 使用与认知功能障碍或痴呆风险的结论时的相对优势和局限性。癌症 2018；124:1326-34。©2018 美国癌症协会。
